On the stock market since 2000, it operates in the world of health and science. It has 316 employees. Now — the numbers.
This is an established company with proven profits.
The gap is $331.9M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 26 buys and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $7.33 — 136% above today’s price.
The company’s market value is 917 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 31/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 47/100.
On our five-subject report card, AGEN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AGEN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (31/100) says the stock isn’t cheap.